| Michael Edwin Fenton, MD | |
|
620 John Paul Jones Cir, Portsmouth, VA 23708-2111 | |
| (757) 953-5000 | |
| Not Available |
| Full Name | Michael Edwin Fenton |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 27 Years |
| Location | 620 John Paul Jones Cir, Portsmouth, Virginia |
| Accepts Medicare Assignments | May be. He may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033183264 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | M-1810 (Guam) | Secondary |
| 2085R0202X | Radiology - Diagnostic Radiology | 00022516 (Alabama) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ybl Pllc | 5395929392 | 3 |
News Archive
Respiratory syncytial virus (RSV) infection is a widespread infant illness that has been linked to asthma and can be deadly but may be curable by the development of this new vaccine technology by the Sir Albert Sakzewski Virus Research Centre and The University of Queensland's Faculty of Biological and Chemical Sciences.
Initial results of the Study of Tamoxifen and Raloxifene, or STAR, show that the drug raloxifene, currently used to prevent and treat osteoporosis in postmenopausal women, works as well as tamoxifen in reducing breast cancer risk for postmenopausal women at increased risk of the disease.
Scientists from the University of Granada have successfully created magnetic bacteria that could be added to foodstuffs and could, after ingestion, help diagnose diseases of the digestive system like stomach cancer.
LEO Pharma today announced that in a Phase III study, PEP005 (ingenol mebutate) Gel, the company's lead candidate for the topical treatment of actinic (solar) keratosis (AK) or pre-cancerous lesions, met its primary clinical endpoint of complete clearance of AK lesions in non-head locations.
ImmusanT announced today that it has initiated clinical trials in New Zealand, Australia and the U.S. to evaluate Nexvax2, the first therapeutic vaccine for patients with celiac disease. Nexvax2 is designed to re-establish patients' tolerance to the toxic effects of gluten, a protein in wheat, barley and rye, and allow them to return to a normal diet.
› Verified 3 days ago
| Entity Name | General Conference Corp Of Sda |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275586877 PECOS PAC ID: 6608777628 Enrollment ID: O20040114000187 |
News Archive
Respiratory syncytial virus (RSV) infection is a widespread infant illness that has been linked to asthma and can be deadly but may be curable by the development of this new vaccine technology by the Sir Albert Sakzewski Virus Research Centre and The University of Queensland's Faculty of Biological and Chemical Sciences.
Initial results of the Study of Tamoxifen and Raloxifene, or STAR, show that the drug raloxifene, currently used to prevent and treat osteoporosis in postmenopausal women, works as well as tamoxifen in reducing breast cancer risk for postmenopausal women at increased risk of the disease.
Scientists from the University of Granada have successfully created magnetic bacteria that could be added to foodstuffs and could, after ingestion, help diagnose diseases of the digestive system like stomach cancer.
LEO Pharma today announced that in a Phase III study, PEP005 (ingenol mebutate) Gel, the company's lead candidate for the topical treatment of actinic (solar) keratosis (AK) or pre-cancerous lesions, met its primary clinical endpoint of complete clearance of AK lesions in non-head locations.
ImmusanT announced today that it has initiated clinical trials in New Zealand, Australia and the U.S. to evaluate Nexvax2, the first therapeutic vaccine for patients with celiac disease. Nexvax2 is designed to re-establish patients' tolerance to the toxic effects of gluten, a protein in wheat, barley and rye, and allow them to return to a normal diet.
› Verified 3 days ago
| Entity Name | Ybl Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295057503 PECOS PAC ID: 5395929392 Enrollment ID: O20120413000671 |
News Archive
Respiratory syncytial virus (RSV) infection is a widespread infant illness that has been linked to asthma and can be deadly but may be curable by the development of this new vaccine technology by the Sir Albert Sakzewski Virus Research Centre and The University of Queensland's Faculty of Biological and Chemical Sciences.
Initial results of the Study of Tamoxifen and Raloxifene, or STAR, show that the drug raloxifene, currently used to prevent and treat osteoporosis in postmenopausal women, works as well as tamoxifen in reducing breast cancer risk for postmenopausal women at increased risk of the disease.
Scientists from the University of Granada have successfully created magnetic bacteria that could be added to foodstuffs and could, after ingestion, help diagnose diseases of the digestive system like stomach cancer.
LEO Pharma today announced that in a Phase III study, PEP005 (ingenol mebutate) Gel, the company's lead candidate for the topical treatment of actinic (solar) keratosis (AK) or pre-cancerous lesions, met its primary clinical endpoint of complete clearance of AK lesions in non-head locations.
ImmusanT announced today that it has initiated clinical trials in New Zealand, Australia and the U.S. to evaluate Nexvax2, the first therapeutic vaccine for patients with celiac disease. Nexvax2 is designed to re-establish patients' tolerance to the toxic effects of gluten, a protein in wheat, barley and rye, and allow them to return to a normal diet.
› Verified 3 days ago
| Entity Name | Takecare Insurance Company Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972565240 PECOS PAC ID: 8325951239 Enrollment ID: O20140918000062 |
News Archive
Respiratory syncytial virus (RSV) infection is a widespread infant illness that has been linked to asthma and can be deadly but may be curable by the development of this new vaccine technology by the Sir Albert Sakzewski Virus Research Centre and The University of Queensland's Faculty of Biological and Chemical Sciences.
Initial results of the Study of Tamoxifen and Raloxifene, or STAR, show that the drug raloxifene, currently used to prevent and treat osteoporosis in postmenopausal women, works as well as tamoxifen in reducing breast cancer risk for postmenopausal women at increased risk of the disease.
Scientists from the University of Granada have successfully created magnetic bacteria that could be added to foodstuffs and could, after ingestion, help diagnose diseases of the digestive system like stomach cancer.
LEO Pharma today announced that in a Phase III study, PEP005 (ingenol mebutate) Gel, the company's lead candidate for the topical treatment of actinic (solar) keratosis (AK) or pre-cancerous lesions, met its primary clinical endpoint of complete clearance of AK lesions in non-head locations.
ImmusanT announced today that it has initiated clinical trials in New Zealand, Australia and the U.S. to evaluate Nexvax2, the first therapeutic vaccine for patients with celiac disease. Nexvax2 is designed to re-establish patients' tolerance to the toxic effects of gluten, a protein in wheat, barley and rye, and allow them to return to a normal diet.
› Verified 3 days ago
| Entity Name | Pacific Radiology Inc A Professional Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023230752 PECOS PAC ID: 9830161546 Enrollment ID: O20181023003439 |
News Archive
Respiratory syncytial virus (RSV) infection is a widespread infant illness that has been linked to asthma and can be deadly but may be curable by the development of this new vaccine technology by the Sir Albert Sakzewski Virus Research Centre and The University of Queensland's Faculty of Biological and Chemical Sciences.
Initial results of the Study of Tamoxifen and Raloxifene, or STAR, show that the drug raloxifene, currently used to prevent and treat osteoporosis in postmenopausal women, works as well as tamoxifen in reducing breast cancer risk for postmenopausal women at increased risk of the disease.
Scientists from the University of Granada have successfully created magnetic bacteria that could be added to foodstuffs and could, after ingestion, help diagnose diseases of the digestive system like stomach cancer.
LEO Pharma today announced that in a Phase III study, PEP005 (ingenol mebutate) Gel, the company's lead candidate for the topical treatment of actinic (solar) keratosis (AK) or pre-cancerous lesions, met its primary clinical endpoint of complete clearance of AK lesions in non-head locations.
ImmusanT announced today that it has initiated clinical trials in New Zealand, Australia and the U.S. to evaluate Nexvax2, the first therapeutic vaccine for patients with celiac disease. Nexvax2 is designed to re-establish patients' tolerance to the toxic effects of gluten, a protein in wheat, barley and rye, and allow them to return to a normal diet.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michael Edwin Fenton, MD 8978 River Cres, Suffolk, VA 23433-1110 Ph: (757) 238-8485 | Michael Edwin Fenton, MD 620 John Paul Jones Cir, Portsmouth, VA 23708-2111 Ph: (757) 953-5000 |
News Archive
Respiratory syncytial virus (RSV) infection is a widespread infant illness that has been linked to asthma and can be deadly but may be curable by the development of this new vaccine technology by the Sir Albert Sakzewski Virus Research Centre and The University of Queensland's Faculty of Biological and Chemical Sciences.
Initial results of the Study of Tamoxifen and Raloxifene, or STAR, show that the drug raloxifene, currently used to prevent and treat osteoporosis in postmenopausal women, works as well as tamoxifen in reducing breast cancer risk for postmenopausal women at increased risk of the disease.
Scientists from the University of Granada have successfully created magnetic bacteria that could be added to foodstuffs and could, after ingestion, help diagnose diseases of the digestive system like stomach cancer.
LEO Pharma today announced that in a Phase III study, PEP005 (ingenol mebutate) Gel, the company's lead candidate for the topical treatment of actinic (solar) keratosis (AK) or pre-cancerous lesions, met its primary clinical endpoint of complete clearance of AK lesions in non-head locations.
ImmusanT announced today that it has initiated clinical trials in New Zealand, Australia and the U.S. to evaluate Nexvax2, the first therapeutic vaccine for patients with celiac disease. Nexvax2 is designed to re-establish patients' tolerance to the toxic effects of gluten, a protein in wheat, barley and rye, and allow them to return to a normal diet.
› Verified 3 days ago
Alexander F Kelley, DO Radiology Medicare: Medicare Enrolled Practice Location: 620 John Paul Jones Cir, Portsmouth, VA 23708 Phone: 757-953-3029 | |
Dr. Glenn Andrew Rauscher, DO Radiology Medicare: Medicare Enrolled Practice Location: 620 John Paul Jones Cir, Portsmouth, VA 23708 Phone: 757-953-0669 | |
Eric Palmer Jones, MD Radiology Medicare: Medicare Enrolled Practice Location: 620 John Paul Jones Cir, Portsmouth, VA 23708 Phone: 757-953-7550 | |
Dr. Christopher Dac Nguyen, M.D. Radiology Medicare: May Accept Medicare Assignments Practice Location: 620 John Paul Jones Cir, Portsmouth, VA 23708 Phone: 757-953-1143 | |
Dr. Andre Chartier, M.D. Radiology Medicare: Medicare Enrolled Practice Location: 620 John Paul Jones Cir, Portsmouth, VA 23708 Phone: 757-953-1128 | |
Cameron Richardson Kendall, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 620 John Paul Jones Cir, Portsmouth, VA 23708 Phone: 757-953-0669 |